Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period
Ciara C. O’Sullivan(Mayo Clinic in Arizona), Karen L. Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vered Stearns(Johns Hopkins University), Mindy S. Christianson(Johns Hopkins University), Christopher B. Umbricht(Johns Hopkins University), Sheeba Irshad(King's College London), Gary L. Rosner(Johns Hopkins University), Zheyu Wang(Second Affiliated Hospital of Nanjing Medical University), Zhuojun Tang(Johns Hopkins University)
Cited by 30
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850